ProQR Therapeutics (PRQR) Accumulated Expenses (2016 - 2022)

ProQR Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $8.9 million for Q4 2022.

• In Q4 2022, Accumulated Expenses fell 28.0% year-over-year to $8.9 million; the TTM figure through Dec 2022 stood at $8.9 million (down 28.0% YoY), while the FY2022 annual figure was $8.9 million, down 30.4% from the prior year.
• Accumulated Expenses came in at $8.9 million for Q4 2022 at ProQR Therapeutics, down from $12.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2021 to a low of $7.3 million in Q4 2020.
• A 5-year average of $9.3 million and a median of $8.9 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 68.75% in 2021 and slipped 28.0% in 2022, its largest moves.
• ProQR Therapeutics' Accumulated Expenses stood at $8.5 million in 2018, then increased by 14.35% to $9.8 million in 2019, then fell by 25.22% to $7.3 million in 2020, then surged by 68.75% to $12.3 million in 2021, then dropped by 28.0% to $8.9 million in 2022.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $8.9 million, $12.3 million, and $7.3 million for Q4 2022, Q4 2021, and Q4 2020 respectively.

Peer Comparison